Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Journal of Pathology, Volume 221, No. 1, Year 2010
Notification
URL copied to clipboard!
Description
Numerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High-grade serous (HGS) carcinoma is the most clinically important histological subtype of ovarian cancer. As these tumours may arise from the ovary, Fallopian tube or peritoneum, they are collectively referred to as high-grade pelvic serous carcinoma (HGPSC). To identify the true prevalence of TP53 mutations in HGPSC, we sequenced exons 2-11 and intron-exon boundaries in tumour DNA from 145 patients. HGPSC cases were defined as having histological grade 2 or 3 and FIGO stage III or IV. Surprisingly, pathogenic TP53 mutations were identified in 96.7% (n = 119/123) of HGPSC cases. Molecular and pathological review of mutation-negative cases showed evidence of p53 dysfunction associated with copy number gain of MDM2 or MDM4, or indicated the exclusion of samples as being low-grade serous tumours or carcinoma of uncertain primary site. Overall, p53 dysfunction rate approached 100% of confirmed HGPSCs. No association between TP53 mutation and progression-free or overall survival was found. From this first comprehensive mapping of TP53 mutation rate in a homogeneous group of HGPSC patients, we conclude that mutant TP53 is a driver mutation in the pathogenesis of HGPSC cancers. Because TP53 mutation is almost invariably present in HGPSC, it is not of substantial prognostic or predictive significance. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC3262968/bin/path0221-0049-SD1.pdf
https://efashare.b-cdn.net/share/pmc/articles/PMC3262968/bin/path0221-0049-SD2.pdf
https://efashare.b-cdn.net/share/pmc/articles/PMC3262968/bin/path0221-0049-SD3.pdf
https://efashare.b-cdn.net/share/pmc/articles/PMC3262968/bin/path0221-0049-SD4.doc
Authors & Co-Authors
Ahmed, Ahmed Ashour
United Kingdom, Cambridge
Cancer Research uk Cambridge Institute
United Kingdom, Cambridge
University of Cambridge
Etemadmoghadam, Dariush
Australia, Melbourne
Peter Maccallum Cancer Centre
Temple, Jillian
United Kingdom, Cambridge
Cancer Research uk Cambridge Institute
United Kingdom, Cambridge
University of Cambridge
Lynch, Andy G.
United Kingdom, Cambridge
University of Cambridge
Riad, Mohamed
Egypt, Cairo
El Galaa Hospital
Sharma, Raghwa N.
Australia, Sydney
The University of Sydney
Stewart, Colin
Australia, Perth
King Edward Memorial Hospital for Women
Fereday, Sian
Australia, Melbourne
Peter Maccallum Cancer Centre
Caldas, Carlos
United Kingdom, Cambridge
University of Cambridge
United Kingdom, Cambridge
Cancer Research uk Cambridge Institute
DeFazio, Anna
Australia, Parramatta
The Westmead Institute for Medical Research
Bowtell, David D.L.
Australia, Melbourne
Peter Maccallum Cancer Centre
Australia, Melbourne
University of Melbourne
Brenton, James D.
United Kingdom, Cambridge
Cancer Research uk Cambridge Institute
United Kingdom, Cambridge
University of Cambridge
Statistics
Citations: 710
Authors: 12
Affiliations: 8
Identifiers
Doi:
10.1002/path.2696
ISSN:
00223417
e-ISSN:
10969896
Research Areas
Cancer
Genetics And Genomics
Study Design
Cross Sectional Study
Cohort Study